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doi:10.1Objectives: Our objectives were to evaluate short- and long-term mortality associated with new-onset atrial fi-
brillation after coronary artery bypass grafting and to identify preoperative and intraoperative patient character-
istics associated with new-onset atrial fibrillation.
Methods: Three independent investigators comprehensively reviewed the literature using Medline from 1960,
Web of Science from 1980, and Scopus from 1960. All searches were done through December 2009. Selected
cohort studies were used to evaluate associations between new-onset atrial fibrillation after coronary artery by-
pass grafting or coronary bypass plus valve and short-term mortality (defined as 30-day or in-hospital mortality)
and long-term mortality (defined as mortality  6 months). We excluded studies involving atrial flutter, off-
pump coronary bypass, and isolated valve surgery. Heterogeneity among studies was accounted for by meta-
analysis with random-effects models.
Results:Eleven studies (n ¼ 40,112) met our inclusion criteria. New-onset atrial fibrillation was associated
with higher short-term mortality (3.6% vs 1.9%; odds ratio [OR], 2.29; 95% confidence interval [CI],
1.74–3.01; P< .00001; heterogeneity of effects, P ¼ .002). Mortality risks at 1 year and 4 years were
2.56 (95% CI, 2.14–3.08) and 2.19 (95% CI, 1.97–2.45; P<.0001), respectively. Older age, lower ejec-
tion fraction, history of hypertension, heart failure, prior stroke, peripheral arterial disease, and longer
cardiopulmonary bypass and aortic clamp times were associated with new-onset atrial fibrillation. Preop-
erative use of ß-blockers reduced occurrence of new-onset atrial fibrillation (OR, 0.94 [95% CI, 0.88–
1.01; P ¼ .08]), whereas angiotensin-converting enzyme inhibitors increased it (OR, 1.20 [95% CI,
1.11–1.29], P< .00001).
Conclusions: New-onset atrial fibrillation after coronary artery bypass grafting appears to increase short- and
long-term mortality. Preoperative use of ß-blockers, avoidance of angiotensin-converting enzyme inhibitors,
and shorter cardiopulmonary bypass and aortic clamp times potentially reduce occurrence of new-onset atrial
fibrillation. (J Thorac Cardiovasc Surg 2011;141:1305-12)New-onset atrial fibrillation (AF) remains the most com-
mon complication after cardiac surgery, with little change
over the past 2 decades. It occurs in 25% to 40% of pa-
tients after coronary artery bypass grafting (CABG) and
in up to 62% after a combined CABG and valve proce-
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The Journal of Thoracic and CarNew-onset AF is widely known to increase morbidity af-
ter cardiac surgery,2-5 and several studies have shown
increased in-hospital and long-term mortality, but this asso-
ciation is not well established or clearly understood.2-8
However, other studies have not reported new-onset AF to
have an independent effect on in-hospital mortality.9 Addi-
tionally, information related to new-onset AF comes mostly
from single-institution studies. Therefore, the primary pur-
pose of our meta-analysis was to evaluate the short- and
long-term mortality of new-onset AF after CABG. Second-
arily, we also evaluated preoperative, intraoperative, and
postoperative variables associated with the occurrence of
new-onset AF.P
MMETHODS
Study Selection
We conducted a comprehensive literature search using Medline from
1960 through December 2009, TheWeb of Science from 1980 through De-
cember 2009, and Scopus from 1960 through December 2009. Wediovascular Surgery c Volume 141, Number 5 1305
Abbreviations and Acronyms
ACEI ¼ angiotensin-converting enzyme
inhibitors
AF ¼ atrial fibrillation
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
COPD ¼ chronic obstructive pulmonary disease
CPB ¼ cardiopulmonary bypass
DM ¼ diabetes mellitus
HF ¼ heart failure
IABP ¼ intra-aortic balloon pumping
LVEF ¼ left ventricular ejection fraction
MI ¼ myocardial infarction
OR ¼ odds ratio
PAD ¼ peripheral arterial disease
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P
Mrestricted our search to observational cohort studies and used the following
key words: AF, cardiac surgery or cardiac surgical procedures or CABG
surgery, mortality or death or outcomes, and determinants or risk factors.
We also used MeSH and TIAB terms for the Medline search. All published
studies that evaluated the occurrence of short-term (in-hospital or within 30
days) and long-term (6 months) mortality in patients with new-onset AF
after CABG with or without valve surgery were identified. In these studies,
new-onset AF was defined as persistent AF of any duration at any time
postoperatively by physician assessment on the basis of a rhythm strip or
12-lead electrocardiographic recording. Results of the combined search
were limited to studies of adult humans published in English, Spanish,
French, and German.
A list of retrieved articles was reviewed independently by 3 investiga-
tors (R.K., I.M., and A.V.H.) to choose potentially relevant articles.
When multiple articles for a single study had been published, we used
the latest publication and supplemented it, if necessary, with data from
earlier publications. Only studies that clearly identified mortality and
perioperative variables in tables or text for both new-onset AF and non–
new-onset AF groups were included in the final data set. We excluded
studies of atrial flutter and tachycardia, off-pump CABG procedures, and
isolated valve surgery. All studies in which the main purpose of the publi-
cation was to evaluate a treatment or intervention were also excluded, un-
less preoperative or intraoperative information was useful for the purpose
of our study.Data Extraction
Data were extracted by 3 investigators (I.M., A.V.H., and R.K.) and the
results compiled. Disagreement was resolved by consensus. Using a stan-
dardized data extraction form, we collected information on lead author,
publication year, study design, sample size, and proportion of patients
with early and latemortality. The following preoperative summary informa-
tion was collected from each study for the new-onset and non–new-onset
AF groups: age, gender, history of hypertension, myocardial infarction
(MI), heart failure (HF), diabetes mellitus (DM), chronic renal insuffi-
ciency, stroke, peripheral arterial disease (PAD), chronic obstructive pul-
monary disease (COPD), and smoking; left ventricular ejection fraction
(LVEF), use of beta-blockers (ß-blockers), angiotensin-converting enzyme
inhibitors (ACEI) and intra-aortic balloon pump (IABP). Information about
intraoperative (cardiopulmonary bypass [CPB] time, use of IABP, aortic
clamp time, and use of inotropes) and postoperative outcomes (length of
hospital stay, respiratory failure, postoperative HF, stroke, and MI) was
also collected.1306 The Journal of Thoracic and Cardiovascular SurValidity and Study Quality Assessment
Prospective cohort studies were considered to be of higher quality than
retrospective cohort studies. Case–control studies that were specifically
designed to assess the influence of risk factors on occurrence of new-
onset AF were considered to be of higher quality than studies that used
a nested case–control design, either by identifying cases of new-onset
AF by hospital discharge registers or by using existing patient registries.
Statistical Analysis
First, we evaluated the association between new-onset AF after CABG
and short- and long-term all-causemortality.We used theMantel–Haenszel
method to calculate pooled odds ratios (OR) and 95% confidence interval
(CI) methods for mortality.10 Because mortality statistics are scarce and the
proportion of new-onset AF patients low, theMantel–Haenszel methodwas
preferred. We also used DerSimonian and Laird random effects models,
and statistical heterogeneity was evaluated as described elsewhere.11 Pub-
lication bias was assessed graphically with funnel plots. We did not have
access to individual patient-level data, and therefore no adjustment was
possible for potential confounders of the association between new-onset
AF andmortality.We used ReviewManager (RevMan, version 5.0 forWin-
dows, Oxford, United Kingdom; The Cochrane Collaboration, 2008).
Long-term mortality was reported at different time points (6 months, 1
and 4 years). We calculated unreported mortality from the reported Ka-
plan–Meier curves when available. With the exception of one, most studies
did not report the number of patients at risk per time point, which discount
patients who died or were lost to follow-up, and we could not use this in-
formation in the analysis. Given the circumstances under which IABP is
used, we chose to combine the reported intraoperative and postoperative
use for purposes of analysis. Preoperative IABP use was analyzed
separately.
Sensitivity Analysis
To explore the strength of the association between new-onset AF and
mortality, we removed studies with fewer than 500 patients with new-
onset AF, removed studies whose populations underwent CABG plus valve
surgery, and used fixed-effects models. After exclusion of studies with
fewer than 500 patients, a total of 38,292 patients remained of whom
28,800 underwent CABGonly. No differences were found between random
and fixed models, and only random-effects models are reported.
We evaluated the association between patient characteristics (preopera-
tive and intraoperative) and new-onset AF. We used the Mantel–Haenszel
method to calculate pooled OR for categorical characteristics or mean dif-
ference for continuous characteristics and their 95% CIs. Also, because
statistically significant clinical heterogeneity among studies was expected,
we used the DerSimonian and Laird random-effects models. Statistical
heterogeneity of effects was evaluated with the Cochran c2 test and the
I2 statistic. The overall effect was calculated with the Z test. Finally, we de-
scribed the associations between postoperative outcomes and new-onset
AF, which do not necessarily have a temporal relationship.RESULTS
Study Characteristics
A total of 927 citations were identified and screened, of
which 46 were retrieved for more detailed information
(Figure 1). Of these, 34 did not fit our criteria, major reasons
for exclusion being inclusion of patients with AF preopera-
tively, heart transplantation, valve-only procedures, and
aortic surgery. We chose 12 studies. We did not get a re-
sponse from the authors of 1 study, and it was eliminated
from the analysis. Thus, we finally included 11 cohort stud-
ies2-9,12-14 (n ¼ 40,112; 5 prospective2,5-8), which weregery c May 2011
927 citations identified and screened 
46 articles retrieved for more detailed 
evaluation
881 excluded after title 
and abstract screening 
12 potential relevant articles 
 34 articles excluded after evaluation: 
• Pre-operative AF (n=9) 
• Other CV surgery or intervention (Valve only, 
heart transplantation, aortic, Fontan, PCI) (n=9)
• No information on mortality (n=5) 
• Primary outcome either Stroke (n=2) or LOS 
(n=3)
• Other arrhythmias (n=2) 
• Other: No control group (n=1), Off-pump 
CABG (n=1), AF as outcome (n=1), 
pharmacological therapy (n=1) 
11 studies included in the meta-analysis 
1 study excluded after 
non-response from 
author
FIGURE 1. Search strategy profile of the meta-analysis. AF, Atrial fibril-
lation; CV, cardiovascular; PCI, percutaneous coronary intervention; LOS,
low-output syndrome; CABG, coronary artery bypass grafting.
Kaw et al Perioperative Managementpublished between 1996 and 2009 (Table 1). Overall, all pa-
tients underwent CABG, 97% underwent CABG only (9
studies), and the remaining 2 studies5,9 included patients
who underwent CABG plus valve surgery.Description of Patient Characteristics
On average, three quarters of patients were male and re-
ceived ß-blockers, two thirds had hypertension, 40% had
prior MI or smoked, a quarter had DM, and 10% had prior
stroke. The means  standard deviations for age and LVEF
were 64 8 years and 54% 13%, respectively. As shown
in Table 1, patients were clinically heterogeneous among
studies.
Intraoperative and postoperative information were not
consistently reported across studies. Mean CPB and aortic
clamp times were 92  35 and 51  22 minutes, respec-
tively; only 2% of patients needed IABP. Inotrope use was
reported in only 3 studies.3,4,14 Among the postoperative
complications, respiratory failure (10%) was the most
common. Other complications were uncommon: HF 3%,
stroke 2%, and MI 4%. Mean postoperative length of stay
was 7.3  4.2 days.P
MAssociation Between Postoperative Non–New-Onset
AF and Both Short- and Long-Term Mortality
All studies evaluated short-termmortality. New-onset AF
was associated with higher short-term mortality (new-onset
AF: 368/10,330 [3.6%] vs non–new-onset AF: 552/29,772
[1.9%]; OR, 2.29; 95% CI, 1.74–3.01; P < .00001;
Figure 2). There was important statistical heterogeneity
among the mortality effects (I2 ¼ 64%, P ¼ .002), and no
evidence of publication bias. The association betweenThe Journal of Thoracic and Carnew-onset AF and short-term mortality remained similar
after removal of studies with fewer than 500 new-onset
AF patients6,12,14 (OR, 2.34 [95% CI, 1.75–3.13]), and
after removal of the 2 studies including CABG plus valve
surgery5,9 (OR, 2.61 [95% CI, 2.06–3.29]).
Five studies evaluated long-term mortality.3-5,7,8 New-
onset AF was also associated with mortality at 1 year3,4,7,8
(new-onset AF: 256/3728 [6.9%] vs non–new-onset AF:
462/13,619 [3.4%]; OR, 2.56 [95% CI, 2.14–3.08];
P<.00001) and at 4 years3,4,7,8 (new-onset AF: 574/3728
[15%] vs non–new-onset AF: 1199/13,619 [8.8%]; OR,
2.19 [95% CI, 1.97–2.45]; P<.00001; Figure 3) . These
risks were similar to the short-term mortality risks. There
was little statistical heterogeneity of the long-term risks
among studies. Only 2 studies4,8 evaluated mortality at 8
years, and risk of mortality was in the same direction
(new-onset AF: 623/2164 [29%] vs non–new-onset AF:
1140/6876 [17%]; OR, 2.01 [95% CI, 1.80–2.25];
P<.00001).
Association of Preoperative, Intraoperative, and
Postoperative Variables With Postoperative New-
Onset AF
Table 2 shows the associations between preoperative and
intraoperative variables and postoperative new-onset AF.
Older age, lower LVEF, prior stroke, and history of hyper-
tension, HF, and PADwere strongly associated with postop-
erative new-onset AF. History of MI and chronic renal
insufficiency also were associated with increased the risk
of new-onset AF, but in lower magnitude. Male gender,
history of DM, and smoking were not associated with
new-onset AF.
Preoperative use of ß-blockers limitedly reduced the
relative risk of new-onset AF by 6% (OR, 0.94 [95% CI,
0.88–1.01], P ¼ .08), and the effects among studies were
consistent (P for heterogeneity ¼ .4). Use of ACEI was as-
sociated with an increased risk of new-onset AF (OR, 1.20
[95% CI, 1.11–1.29]; P<.00001). However, this associa-
tion was based on only 3 studies. Four studies3,6,7,9
reported preoperative IABP and this was associated with
new-onset AF (OR, 1.46 [95% CI, 1.25–1.70]; P<.00001).
Six studies2,4,5,8,13,14 reported that longer CPB time was
associated with new-onset AF (mean difference, 4.73
[95% CI, 2.40–7.05]; P< .0001), and 5 studies2,4,8,13,14
reported that longer aortic clamp time was associated with
new-onset AF (mean difference, 4.13 [95% CI, 1.81–
6.45]; P ¼ .0005). Five studies2,6,7,9,14 reported
postoperative and 1 study4 reported intraoperative IABP
use. We found a weak relation between intraoperative/post-
operative use of IABP and new-onset AF (OR, 1.57 [95%
CI, 0.92–2.66]; P ¼ .10). Use of intraoperative inotropes
was also associated with new-onset AF (OR, 2.05 [95%
CI, 1.15–3.65];P¼ .02). All these associations were hetero-
geneous among studies.diovascular Surgery c Volume 141, Number 5 1307
TABLE 1. Preoperative patient characteristics in studies included in the meta-analysis
Study reference, year N % CABG only Type of overall mortality
Age (y),
mean (SD)
Men,
n (%)
Ahlsson et al,8 2009 1,419 100 IHM up to 9 y 65.7 (9.1) 1,068 (75)
Almassi et al,5 1997* 3,855 81 IHM 6 mo 63.7 (9.4) 3,795 (98)
Aranki et al,6 1996 5,70 100 IHM 71.5y 395 (69)
Echahidi et al,13 2007 5,086 100 IHM 64.0 (7.1) 3,892 (77)
Hravnak et al,12 2002 814 100 IHM 65.5 (9.5) 546 (67)
Kalavrouziotis et al,9 2007y 7,347 92 IHM NA 5,433 (74)
Mariscalco et al,7 2008 1,832 100 IHM up to 6 y 65.2 (8.6) 1,448 (79)
Mariscalco et al,4 2009 7,621 100 IHM up to 12 y 64.6 (8.6) 5,830 (77)
Mathew et al,2 2004 4,657 100 IHM 63.7 (9.2) 3,716 (80)
Nisanoglu et al, 14 2007 426 100 IHM 70.1 (4.4) 296 (69)
Villareal et al,3 2004 6,475 100 IHM up to 4 y 63.1 (10.5) 4,780 (74)
Total 40,112 97 64.4 (7.6) 31,199 (78)
CABG, Coronary artery bypass grafting; SD, standard deviation;HTN, hypertension;DM, diabetes mellitus;COPD, chronic obstructive pulmonary disease; LVEF, left ventricular
ejection fraction; MI, myocardial infarction; BB, Use of ß-blockers; IHM, in-hospital mortality; NA, not available; stroke, prior stroke. *Includes patients with CABG only and
CABG plus valve. yMedian. zNumber of patients with LVEF>40%.
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P
MWe also evaluated the relationship between postopera-
tive outcome variables and new-onset AF, although most
studies did not specify whether these complications pre-
ceded or followed the occurrence of new-onset AF. Postop-
erative stroke (OR, 2.23 [95% CI, 1.78–2.80]) and
respiratory failure (OR, 2.30 [95% CI, 1.71–3.11]) were
associated with higher risk of new-onset AF. Postoperative
MI (OR, 0.98 [95% CI, 0.56–1.71]) and HF (OR, 1.82
[95% CI, 0.78–4.23]) were not related to new-onset AF.
Patients experiencing new-onset AF had a longer postoper-
ative length of stay by median 1.48 days (95% CI,
1.09–1.87 days)
DISCUSSION
Principal Findings
Mortality. Our analysis provides convincing evidence that
both short- and long-term mortality are increased whenStudy or Subgroup
Ahlsson 2009
Almassi 1997
Aranki 1996
Echahidi 2007
Hravnak 2002
Kalavrouziotis 2007
Mariscalco 2008
Mariscalco 2009
Mathew 2004
Nisanoglu 2007
Villareal 2004
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.11; Chi² = 27.62, df = 10 (P = 0.002); I² = 64
Test for overall effect: Z = 5.90 (P < 0.00001)
Events
8
68
7
40
2
61
19
16
71
2
74
368
Total
419
1143
189
1369
260
2047
570
1745
1503
91
994
10330
Events
5
80
6
34
0
133
7
24
66
11
186
552
Total
1000
2712
381
3717
554
5300
1262
5876
3154
335
5481
29772
Weight
4.5%
14.5%
4.6%
12.1%
0.8%
15.0%
6.5%
9.3%
14.4%
2.8%
15.5%
100.0%
AF non-AF
FIGURE 2. Short-term mortality risks associated with new-onset atrial fibrillat
1308 The Journal of Thoracic and Cardiovascular Surnew-onset AF is diagnosed after CABG. The increase in
in-hospital mortality was seen in all studies included in
the meta-analysis. Although heterogeneous, the effect per-
sisted after excluding studies with small numbers of pa-
tients and studies of combined CABG and valve surgery.
The effect of new-onset AF on mortality persisted at 6
months, 1 year, and 4 years and was similar to short-term
mortality risk, although only a few long-term studies were
available.
Earlier studies did not report increased mortality from
new-onset AF after cardiac surgery. Recently, Kalavrouzio-
tis and associates9 did not report new-onset AF to have an
independent effect on in-hospital mortality (OR, 0.8
[95% CI, 0.6–1.2]) in 2 comparable risk-adjusted and
propensity-matched groups of patients after cardiac surgery.
The study, however, lacked data on use of rate or rhythm
control medication postoperatively. The earliest data on%
M-H, Random, 95% CI
3.87 [1.26, 11.91]
2.08 [1.49, 2.90]
2.40 [0.80, 7.26]
3.26 [2.06, 5.17]
10.73 [0.51, 224.20]
1.19 [0.88, 1.62]
6.18 [2.58, 14.79]
2.26 [1.20, 4.26]
2.32 [1.65, 3.26]
0.66 [0.14, 3.04]
2.29 [1.73, 3.02]
2.29 [1.74, 3.01]
Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
AF better AF worse
ion. AF,Atrial fibrillation;M–H,Mantel–Haenszel; CI, confidence interval.
gery c May 2011
HTN,
n (%)
DM,
n (%)
Stroke,
n (%)
COPD,
n (%)
Smoking,
n (%)
LVEF,
mean (SD)
MI,
n (%)
BB use,
n (%)
531 (37) 243 (17) 95 (7) NA 835 (58) 57.7 (12) 825 (58) NA
2,273 (59) NA 692 (18) 589 (15) 1,012 (26) NA 1,972 (51) 2,265 (59)
336 (59) 173 (30) 90 (16) 51 (9) 144 (25) NA 343 (60) 430 (75)
3,272 (64) 1,594 (31) 253 (5) 509 (10) NA 59.6 (14) 2,490 (49) 4,031 (79)
NA 230 (28) NA 91 (11) NA NA 236 (29) NA
4,479 (61) 2,430 (33) 932 (13) 994 (14) NA 6,463z NA 6,189 (84)
1,017 (56) 491 (27) 106 (6) 138 (8) 444 (24) 54.7 (11.1) 397 (51) 1,279 (70)
4,631 (61) 1,676 (22) 659 (9) NA NA NA NA NA
3,113 (67) 1,442 (31) 481 (10) 532 (11) NA NA 2,952 (63) 3,235 (69)
178 (42) 79 (19) 100 (23) 89 (21) 211 (50) 48.2 (10.6) 309 (73) 180 (42)
4,421 (68) 710 (11) 385 (6) 1,497 (23) 3,503 (54) 49.3 (13.2) 1,017 (16) NA
24,252 (62) 9,068 (25) 3,793 (10) 4,490 (14) 6,149 (42) 54.1 (12.7) 11,081 (44) 17,609 (74)
TABLE 1. Continued
Kaw et al Perioperative Managementthe association of new-onset AF after cardiac surgery with
intermediate-term (6-month) mortality were reported by
Almassi and colleagues5 (new-onset AF 9.4% vs non–
new-onset AF 4.2%; P< .001). Villareal and associates3
also found that new-onset AF was associated with a higher
risk of in-hospital mortality (OR, 1.5 [95% CI, 1.3–1.8];
P<.0001). So that its impact on estimates of later outcomes
would be reduced, in-hospital mortality was censored, but
the adverse mortality persisted after case–control matching
(OR, 3.4 [95% CI, 1.6–7.5]). More important, however, the
etiology and pathophysiology of new-onset AF still remain
largely unclear.15
Five studies looked at long-term mortality from new-
onset AF after CABG.3-5,7,8 Of these, only 2 studies7,8
specifically investigated autopsy results, with 82 and 331
deaths, respectively. Mariscalco and colleagues7 followed
1832 patients (570 with new-onset AF) for up to 6 years
and Ahlsson and colleagues8 followed 1419 patients (419
with new-onset AF) up to 9 years after CABG. A higher
number of deaths owing to cerebral events (51/82 vs 20/
419) was reported by Mariscalco and colleagues,7 although
some of the difference in mortality resulting from cerebral
events could be related to how new-onset AF was treated.
Direct-current cardioversion was tried at the first postoper-
ative visit, after previously attempted pharmacologic cardi-
oversion had failed. In Ahlsson and colleagues’ study,8 theStudy or Subgroup
Ahlsson 2009
Mariscalco 2008
Mariscalco 2009
Villareal 2004
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.81, df = 3 (P = 0.61); I² = 0%
Test for overall effect: Z = 14.01 (P < 0.00001)
Events
50
57
209
258
574
Total
419
570
1745
994
3728
Events
70
63
353
713
1199
Total
1000
1262
5876
5481
13619
Weight
8.3%
8.7%
37.2%
45.9%
100.0%
AF non-AF
FIGURE 3. Four-year mortality risks associated with new-onset atrial fibrillati
The Journal of Thoracic and Carmain treatment for new-onset AF was electrical as opposed
to pharmacologic cardioversion (with amiodarone) and
ischemic/embolic strokes were confirmed in all patients
by computed tomography.
More patients (70/140) with new-onset AF died of car-
diac causes (including MI and congestive HF) in Ahlsson
and colleagues’ study8 than of similar causes in the Maris-
calco study7 (31/82).The number of deaths from acute MI
and HF were too low for any predictive estimate but seemed
to occur constantly during the follow-up time frame. A con-
stant hazard rate was demonstrated in a subsequent study,4
which did not report autopsy data. There seemed to be an
earlier trend to mortality from cerebral events in the study
by Mariscalco and colleagues.7 To see whether there were
any differences over time, Ahlsson and associates8 sepa-
rated the patients postoperatively into groups with and with-
out AF, but no differences were noted with respect to any
single cause of death.
The mechanisms by which new-onset AF is associated
with higher mortality are purely speculative and beyond
the scope of our analysis. It is currently unknown whether
patients who have new-onset AF can also have left ventric-
ular dysfunction, chronic or persistent AF, or thromboem-
bolic phenomena. Some case series and animal
experiments have shown that AF with rapid ventricular re-
sponse can predispose to dilated cardiomyopathy withinM-H, Random, 95% CI
1.80 [1.23, 2.64]
2.11 [1.46, 3.07]
2.13 [1.78, 2.55]
2.34 [1.99, 2.76]
2.19 [1.97, 2.45]
Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
AF better AF worse
on. AF, Atrial fibrillation;M–H,Mantel–Haenszel; CI, confidence interval.
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TABLE 2. Association between preoperative, intraoperative, and postoperative variables and postoperative new-onset AF
New-onset AF*
Variable
No. of
studies Yes No
Association effect
[95% CI]
P for
effect
P for
heterogeneity
Preoperative
Age (y) 9 68.2 (6.3)
(n ¼ 8,094)
63.1 (8.1)
(n ¼ 24,091)
MD 4.73 [4.01-5.45] <.00001 <.00001
Male gender 11 8,133/10,330
(78.7%)
23,068/29,772
(77.5%)
OR 1.04 [0.97-1.12] .3 .2
Hypertension 10 6,465/10,070
(64.2%)
17,786/29,218
(60.9%)
OR 1.19 [1.13-1.26] <.00001 .3
Prior stroke 10 1,229/10,070
(12.2%)
2,564/31,545
(8.1%)
OR 1.42 [1.16-1.72] .0005 <.00001
MI 9 3,236/6,457
(50.1%)
7,845/18,449
(42.5%)
OR 1.10 [1.02-1.17] .01 .3
HF 5 1,185/4,993
(23.7%)
2,487/14,870
(16.7%)
OR 1.39 [1.28-1.51] <.00001 .7
PAD 8 1,464/8,282
(17.7%)
3,321/24,501
(13.6%)
OR 1.37 [1.20-1.58] <.00001 .003
DM 10 2,464/9,187
(26.8%)
6,605/26,960
(24.5%)
OR 0.99 [0.90-1.10] 0.9 .007
Chronic renal insufficiency 4 299/3,702
(8.1%)
827/12,378
(6.1%)
OR 1.58 [1.11-2.24] .01 .008
COPD 9 1,367/8,166
(16.7%)
3,123/22,896
(13.6%)
OR 1.45 [1.35-1.56] <.00001 .9
Smoking 6 1,256/3,401
(36.9%)
4,895/11,156
(43.9%)
OR 0.90 [0.74-1.10] .3 .0007
LVEF (%) 5 54.7 (12.1)
(n ¼ 3,443)
54.0 (13.3)
(n ¼ 11,795)
MD0.92 [1.43,0.40] .0005 .7
ß-Blocker use 7 5,049/6,899
(73.2%)
12,560/16,845
(74.6%)
OR 0.94 [0.88-1.01] .08 .4
ACEI use 3 1,875/4,120
(45.5%)
3,983/9,716
(41.0%)
OR 1.20 [1.11-1.29] <.00001 .7
Intraoperative
CPB time (min) 6 97.1 (35.7)
(n ¼ 6,270)
90.0 (35.4)
(n ¼ 16,794)
MD 4.73 [2.40–7.05] <.0001 .0003
AC time (min) 5 55.4 (23.4)
(n ¼ 5,127)
49.9 (21.6)
(n ¼ 14,082)
MD 4.13 [1.81–6.45] .0005 <.0001
Use of IABP 6 161/6,145
(2.6%)
296/16,308
(1.8%)
OR 1.57 [0.92-2.66] .1 <.0001
Use of inotropes 3 685/2,830
(24.2%)
1,580/11,692
(13.5%)
OR 2.05 [1.15–3.65] .02 <.00001
Postoperative
Stroke 11 335/10,328
(3.2%)
468/29,769
(1.6%)
OR 2.23 [1.78-2.80] <.00001 .04
Respiratory failure 5 608/3,589
(16.9%)
1,221/13,335
(9.2%)
OR 2.30 [1.71-3.11] <.00001 .0006
HF 4 168/3,824
(4.4%)
333/11,725
(2.8%)
OR 1.82 [0.78-4.23] .2 <.00001
MI 7 241/6,527
(3.7%)
858/18,621
(4.6%)
OR 0.98 [0.56-1.71] .9 <.00001
Length of stay (d) 6 9.8 (5.0)
(n ¼ 5,157)
8.2 (3.9)
(n ¼ 14,017)
MD 1.48 [1.09–1.87] <.00001 <.0001
AF, Atrial fibrillation; CI, confidence interval;MD,mean difference; OR, odds ratio;MI,myocardial infarction; HF, heart failure; PAD, peripheral arterial disease; DM, diabetes
mellitus;COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction;ACEI, angiotensin-converting enzyme inhibitors;CPB, cardiopulmonary bypass;
AC, aortic clamp; IABP, intra-aortic balloon pump;MI,myocardial infarction. *Shown as weighted mean (standard deviation) (total) for continuous variables and n/total (%) for
categorical variables.
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Mweeks.16 Higher release of creatine kinase MB has been
reported in patients with new-onset AF as compared with
patients without new-onset AF, implying a myocardial in-
jury mechanism.17 Increased mortality from new-onset AF
may also be related to its treatment, especially with antiar-
rhythmic medications and anticoagulants. In regard to late
mortality with autopsy data, both authors (Mariscalco and
Ahlsson) explain late mortality on the basis of higher
propensity for subsequent atrial arrhythmias, although the
1-year prevalence of AF after cardiac surgery is reported
at 1% to 2%.18 Only 1 study5 looked at the absence of
predischarge AF and showed that AF occurring during
follow-up in the group without predischarge AF (but not
in the group with predischarge AF) significantly increased
the risk of death (hazard ratio 4.44 [1.23–15.99],
P ¼ .023).
Factors associated with new-onset AF. Among the pre-
dictive factors for new-onset AF, age,1 COPD,2 lower
LVEF, prior stroke and PAD, and preoperative IABP use
were associated with new-onset AF. Interestingly, our study
reports increased risk of new-onset AF from preoperative
use of ACEI before CABG. Higher risk of new-onset AF
(OR, 1.33 [95% CI, 1.17–1.51]; P<.0001) and a doubling
in mortality risk (OR, 2.83 [95% CI, 1.03–7.8]; P ¼ .04)
secondary to preoperative ACEI use was also recently
shown by Miceli and colleagues19 in 3052 patients receiv-
ing preoperative ACEI matched 1:1 to a control group by
propensity score analysis. A recent study20 showed benefit
with regard to reduction in new-onset AF, whereas others
have not shown any benefit.21,22 ACEIs are widely known
to decrease the risk of AF after MI and cardioversion,
but the antiarrhythmic effect of ACEI/angiotensin
receptor blocking agents after cardiac surgery at present is
at best theoretical. Several mechanisms involving atrial
remodeling, including angiotensin II–dependent atrial
fibrosis and regulation of angiotensin II–receptor
subtypes, have been postulated. Candesartan has been
shown to prevent structural atrial remodeling and atrial
endothelial dysfunction in hypertensive rats.23 Given the
limitations of our analysis, we cannot claim that preopera-
tive use of ACEI is independently associated with new-
onset AF after CABG.
As is widely known, sympathovagal imbalance 24 may be
an important trigger for postoperative new-onset AF; the ef-
fect of ß-blockers on new-onset AF is thus important but
controversial. Some factors make this issue complex. First,
it is common practice to routinely use ß-blockers before sur-
gery and to continue in the postoperative period, yet in
many cases they may be inadvertently discontinued and
not resumed in a timely manner postoperatively. In our
analysis, preoperative ß-blocker use was fairly comparable
between patients in whom new-onset AF developed postop-
eratively and those in whom it did not, and ß-blockers were
shown to be beneficial.The Journal of Thoracic and CarAmong the intraoperative factors, CPB time and aortic
clamp time were associated with new-onset AF. Aortic
clamp time has been proposed as one of the main intraoper-
ative factors predisposing to new-onset AF; however, other
studies have not shown this association.25
Limitations
Our study has several limitations. First, and perhaps most
important, is that several factors related to new-onset AF
also predict early and late mortality.3-5 Distinguishing
these complications arising out of new-onset AF from the
risks related to pre-existing cardiac disease underscores
the daunting task of establishing new-onset AF as an inde-
pendent contributor to mortality. Meta-analyses of pub-
lished studies by concept allow univariate analysis only
and are in no position to address that question. Second,
incomplete matching led to exclusion of large numbers of
patients in other studies.4,5 particularly in the study by
Villareal and colleagues,3 in which less than 20% of AF
cases were represented in the matched-set analysis. Al-
though other studies7,9 used propensity score matching,
this still does not overcome the potential limitation posed
by unrecognized and unmeasured confounders. Third,
mortality data in most studies were based on all-cause mor-
tality because of limited autopsy data; as such, the mecha-
nisms of postoperative AF-associated mortality remain at
best speculative. Fourth, information on long-term mortal-
ity risks in individual studies was scarce. With the exception
of Mariscalco and colleagues,7 published risks did not
discount patients who had already died or were lost to
follow-up at given time points. This may have introduced
bias in calculations of long-term ORs for mortality. Using
the information supplied by Mariscalco and associates,7
we performed a sensitivity analysis to calculate ORs with
2 different denominators (number of patients at baseline
versus number of patients at the beginning of the period
of interest), and similar ORs were obtained at 6 months, 1
year, and 4 years, probably owing to a low mortality risk
on this study. However, this was not the case in other stud-
ies, and the risk of bias is still present. Fifth, because our
analysis includes several retrospective studies, we cannot
exclude the possibility that new-onset AF occurred as a con-
sequence of another postoperative complication, that is, it
was a surrogate marker of poor outcome. To overcome
this effect, Villareal and colleagues3 censored in-hospital
mortality while making such comparisons, but the associa-
tion between new-onset AF and reduced survival persisted.
Sixth, new-onset AF occurs at different times in different
patients, but none of the studies attempted to find associa-
tions between temporal onset of new-onset AF and
time-specific risk factors, nor did they investigate the condi-
tion of patients at the onset of new-onset AF to identify pos-
sible inciting factors. Thus, in this meta-analysis it was not
possible to investigate the impact of an active clinicaldiovascular Surgery c Volume 141, Number 5 1311
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Mcondition or complication at the onset of new-onset AF, nor
its immediate consequences, such as occasional acute he-
modynamic deterioration secondary to lack of synchronized
atrial contraction that may be particularly important for pa-
tients with diastolic dysfunction. Last, the studies did not
carry enough information regarding medications to explain
whether increased postoperative mortality could be related
to treatment of new-onset AF or undertreatment of potential
thromboembolic risk. In observational studies, sicker pa-
tients are often treated, and hence the effects of treatment
on outcome are difficult to delineate. However, most centers
currently tend to tackle new-onset AF by a formal or infor-
mal protocol requiring anticoagulation and chemical or
electrical cardioversion, especially if new-onset AF causes
hemodynamic compromise.
CONCLUSIONS
Implications for Clinical Practice
Results from the pooled data are too compelling to disre-
gard the association between new-onset AF and early and
late mortality after cardiac surgery. Among the modifiable
factors, whenever possible less or judicious use of inotropes
may help lower the occurrence of new-onset AF, as may
shorter CPB and aortic clamp times during the surgery.
Increased use of ß-blockers, on the other hand, may also
decrease occurrence of new-onset AF. Postoperative/intrao-
perative IABP use was not associated with new-onset AF.
Implications for Research
No evidence to support any pathophysiologic mecha-
nisms linking new-onset AF to mortality exists at this
time. Risk factors for mortality in cardiac surgical patients
are widely established, but risk factors for new-onset AF
have not been well studied, and probably some of them
are also risk factors for mortality. Whether this association
can be explained by other variables, such as common risk
factors for new-onset AF and mortality, remains to be inves-
tigated. We could not adjust for these confounders, inas-
much as we used published summary data and did not
have access to individual patient data. Future studies need
to consider these factors as well as the potential issue of
mortality related to treatment of new-onset AF with antiar-
rhythmics or undertreatment of new-onset AF, particularly
in regard to anticoagulation.
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